GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diagonal Bio AB (OSTO:DIABIO) » Definitions » Intrinsic Value: Projected FCF

Diagonal Bio AB (OSTO:DIABIO) Intrinsic Value: Projected FCF : kr0.00 (As of Dec. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Diagonal Bio AB Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-12-11), Diagonal Bio AB's Intrinsic Value: Projected FCF is kr0.00. The stock price of Diagonal Bio AB is kr0.0253. Therefore, Diagonal Bio AB's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Diagonal Bio AB's Intrinsic Value: Projected FCF or its related term are showing as below:

OSTO:DIABIO's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.395
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Diagonal Bio AB Intrinsic Value: Projected FCF Historical Data

The historical data trend for Diagonal Bio AB's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diagonal Bio AB Intrinsic Value: Projected FCF Chart

Diagonal Bio AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - -

Diagonal Bio AB Quarterly Data
Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Diagonal Bio AB's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Diagonal Bio AB's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diagonal Bio AB's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diagonal Bio AB's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Diagonal Bio AB's Price-to-Projected-FCF falls into.



Diagonal Bio AB Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Diagonal Bio AB  (OSTO:DIABIO) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Diagonal Bio AB's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0253/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diagonal Bio AB Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Diagonal Bio AB's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Diagonal Bio AB Business Description

Industry
Traded in Other Exchanges
Address
The Spark, Medicon Village, Lund, SWE, 223 81
Diagonal Bio AB is developing a diagnostic platform for ultra-rapid, parallel, accurate and cost-efficient detection of any kind of pathogen - Panviral.

Diagonal Bio AB Headlines

No Headlines